Background
Development of a telmisartan‐based suppression test may facilitate the diagnosis of primary hyperaldosteronism (PHA) in cats, which remains difficult today.
Objectives
To develop a ...telmisartan suppression test (TST) that is safe, and able to suppress aldosterone secretion in healthy cats but not in cats with PHA.
Animals
Ten healthy cats and 6 cats with PHA.
Methods
Prospective study using a placebo‐controlled crossover design to investigate a TST in healthy cats, and evaluation of TST in cats with PHA. Plasma aldosterone concentration, potassium concentration, and systolic blood pressure (SBP) were measured before (T0), and 1 hour (T1) and 1.5 hours after (T1.5) PO administration of 1 mg/kg of telmisartan, 2 mg/kg of telmisartan or placebo.
Results
Median age in healthy cats was 3 years old (range, 1‐7). In healthy cats, a telmisartan dose of 2 mg/kg significantly decreased aldosterone concentration at T1 and T1.5 compared with T0. Placebo had no significant effect on aldosterone concentration. In cats diagnosed with PHA, a 2‐mg/kg dose of telmisartan did not induce any significant change in aldosterone concentration at T1 or T1.5 compared with T0. No adverse effects of telmisartan (e.g., hyperkalemia, systemic hypotension) were observed in any cats.
Conclusions and Clinical Importance
The oral TST shows promise as a diagnostic test for the diagnosis of PHA in cats.
Background
Successful treatment of cats with hypersomatotropism by transsphenoidal hypophysectomy is described in small numbers of cats.
Objectives
To describe the endocrine profile, survival, and ...remission rates of hypersomatotropism and diabetes mellitus in a cohort of cats with hypersomatotropism that underwent hypophysectomy between 2008 and 2020.
Animals
Twenty‐five client‐owned cats with spontaneous hypersomatotropism.
Methods
Retrospective study. Diagnosis of hypersomatotropism was based on clinical signs, plasma insulin‐like growth factor‐1 (IGF‐1) concentration, and imaging of the pituitary gland. Growth hormone (GH) and IGF‐1 concentrations were measured repeatedly after surgery. Survival times were calculated based on follow‐up information from owners and referring veterinarians.
Results
Median postoperative hospital stay was 7 days (range, 3‐18 days). One cat died within 4 weeks of surgery. Median plasma GH concentration decreased significantly from 51.0 ng/mL (range, 5.0‐101.0 ng/mL) before surgery to 3.8 ng/mL (range, 0.6‐13.0 ng/mL) at 5 hours after surgery. Remission of hypersomatotropism, defined as normalization of plasma IGF‐1 concentration, occurred in 23/24 cats (median, 34 ng/mL; range, 14‐240 ng/mL) and 22/24 cats entered diabetic remission. Median survival time was 1347 days (95% confidence interval, 900‐1794 days; range, 11‐3180 days) and the overall 1‐, 2‐, and 3‐year all‐cause survival rates were 76%, 76%, and 52%, respectively.
Conclusions and Clinical Importance
This study shows the beneficial outcome of hypophysectomy in cats with hypersomatotropism, marked by low death rate and a high percentage of diabetic remission and definitive cure.
Case summary A 10-year-old neutered male domestic shorthair cat was diagnosed with renal adenocarcinoma associated with hypertrophic osteopathy. The cat was referred for chronic ambulation ...difficulties. The physical examination showed a painful thickening of all four limbs, a right cranial abdominal mass and a conjunctival hyperaemia. Radiographic findings were consistent with extensive periosteal new bone formation involving not only the diaphyses of the fore- and hindlimbs, but also of the pelvis, tarsus and carpus. Abdominal ultrasonography and CT revealed a mass within the right kidney and a primary neoplasm was suspected. A ureteronephrectomy of the right kidney was performed and histopathology confirmed the diagnosis of renal adenocarcinoma. Although clinical improvement of the lameness occurred after surgery, no radiographic changes of hypertrophic osteopathy lesions were observed at the 9-month follow-up. Relevance and novel information Feline cases of hypertrophic osteopathy are rarely reported in the literature and only a few of them were associated with abdominal neoplastic diseases. To our knowledge, this is the first case of renal adenocarcinoma associated with hypertrophic osteopathy in a cat.
In the Long Shadows X-Rays Whiten Rosenberg, Dan (American poet)
The Literary review (Teaneck),
03/2016, Letnik:
59, Številka:
2
Journal Article, Magazine Article
Acromégalie féline et comparée Rosenberg, Dan
Bulletin de l'Académie vétérinaire de France/Bulletin de l'Académie vétérinaire de France,
2022, Letnik:
175
Journal Article
Odprti dostop
La caractérisation de l’acromégalie féline s’effectue à marche rapide depuis une quinzaine d’années et démontre une forte similitude avec son homologue décrite dans l’espèce humaine. Ce manuscrit ...passe en revue de nombreux points de convergences à commencer par la présence d’une tumeur hypophysaire responsable d’une sécrétion dérégulée d’hormone de croissance dans les deux espèces. Elles partagent également une forte proportion de sous diagnostics liées à une expression clinique souvent fruste et d’installation progressive mêlant des modifications morphologiques et des troubles de l’homéostasie du glucose pouvant aller jusqu’au diabète sucré, presque systématique à l’heure actuelle parmi les chats atteints alors qu’une moitié au plus des patients humains acromégales présentent cette comorbidité. Le diagnostic s’appuie sur des techniques d’imagerie en coupe du diencéphale après mise en évidence d’une mesure supérieure à intervalle de référence de la concentration sérique du second messager de l’hormone de croissance, l’insulin like growth factor I (IGF-1). Un traitement causal (geste chirurgical, radiothérapie, traitement médical antisécrétoire) apparaît enfin prioritaire dans les deux espèces, en parallèle de l’équilibre d’un diabète sucré, lorsque celui-ci est présent.
Feline acromegaly has been characterized by veterinarians, over the last 15 years mainly, resulting in the demonstration of a strong similarity with its human counterpart. This manuscript underlines many points of convergence between feline and human species, starting with the presence of a pituitary tumour responsible for a deregulated secretion of growth hormone. Humans and cats also share a high proportion of underdiagnosis related to insidious clinical features consisting in morphological changes and disorders of glucose homeostasis like diabetes mellitus, almost systematic in feline species and observed in at most fifty percent of the cases of human acromegalic patients. Identification of a serum concentration above reference range of the of insulin like growth factor I (IGF-1), the second messenger of the growth hormone, is the cornerstone of diagnosis in both species. It is followed by the demonstration of a pituitary tumour by CT scan or MRI examination. Etiological treatment (surgery, radiotherapy, antisecretory medical treatment) in generally necessary in both species, complemented by the control of diabetes mellitus when this disease is present.
PDF
